Marrone Bio Innovations Inc (NASDAQ:MBII) – Equities researchers at Jefferies Group reduced their FY2018 EPS estimates for Marrone Bio Innovations in a research report issued on Tuesday, April 3rd. Jefferies Group analyst L. Alexander now forecasts that the basic materials company will earn ($0.14) per share for the year, down from their previous forecast of ($0.13). Jefferies Group has a “Hold” rating and a $1.55 price target on the stock. Jefferies Group also issued estimates for Marrone Bio Innovations’ FY2019 earnings at ($0.12) EPS.
MBII has been the topic of a number of other research reports. ValuEngine raised Marrone Bio Innovations from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research lowered Marrone Bio Innovations from a “hold” rating to a “sell” rating in a report on Thursday, February 15th. Finally, HC Wainwright set a $4.00 price objective on Marrone Bio Innovations and gave the company a “buy” rating in a report on Thursday, December 21st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. Marrone Bio Innovations has a consensus rating of “Hold” and an average price target of $2.18.
Shares of MBII opened at $3.25 on Thursday. Marrone Bio Innovations has a twelve month low of $0.85 and a twelve month high of $3.39. The company has a market capitalization of $259.08, a price-to-earnings ratio of -3.04 and a beta of -0.54. The company has a debt-to-equity ratio of -1.14, a quick ratio of 0.36 and a current ratio of 0.69.
Marrone Bio Innovations (NASDAQ:MBII) last released its quarterly earnings results on Thursday, March 29th. The basic materials company reported ($0.24) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.02. The company had revenue of $3.32 million for the quarter.
In other Marrone Bio Innovations news, insider Ardsley Advisory Partners acquired 6,666,667 shares of the stock in a transaction on Monday, February 5th. The shares were bought at an average price of $0.75 per share, with a total value of $5,000,000.25. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 2.80% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Jefferies Group Weighs in on Marrone Bio Innovations Inc’s FY2018 Earnings (MBII)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/jefferies-group-weighs-in-on-marrone-bio-innovations-incs-fy2018-earnings-mbii.html.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.
Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.